Cytox Plans US Clinical Launch for Early-Stage Alzheimer's Test While Courting Pharma Partners
May 03, 2017 Justin Petrone www.genomeweb.com British molecular diagnostics company Cytox plans to make…
read moreCytox is developing a diagnostic test and therapeutic cures for Alzheimer’s Disease which is estimated to affect 15 million people worldwide. The company is a university spin-out based on groundbreaking academic research into the role of the cell cycle in neuro-degenerative diseases.
Status current
Associated Fund
Advantage Growth Fund,
UK Innovation & Science Seed Fund
Sector Medical / Biotechnology
Website www.cytoxgroup.com
May 03, 2017 Justin Petrone www.genomeweb.com British molecular diagnostics company Cytox plans to make…
read more20 July 2015: Oxford, UK. Cytox Ltd, an innovative developer of assays for risk assessment…
read moreImportant research collaboration for pioneering PRS approach to help drug developers running clinical trials...
read moreCytox Expands Collaboration with AIBL to Identify Those Most at Risk to Rapidly Progress...
read more